FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3041486231> ?p ?o ?g. }

• W3041486231 endingPage "153116" @default.
• W3041486231 startingPage "153116" @default.
• W3041486231 abstract "As more and more molecular markers have been identified in Intrahepatic Cholangiocarcinoma (ICC), target treatments are promising all around the world. However, geographical and ethnic variations in the ICC epidemiology suggest different genetic variance prevalence in western and eastern countries. Six genetic variations in Chinese ICC populations were analyzed by fluorescent in situ hybridization (FISH) or Sanger sequencing, listed as IDH1/2 mutation, FGFR2 translocation, NTRK1 amplification, MDM2 amplification, HER2 amplification and MET amplification, all of which have corresponding target drugs; meanwhile, they were compared with these gene prevalence in Spanish population based on the cBioPortal database. The incidences of IDH1/2 mutation, FGFR2 translocation, NTRK1 amplification, MDM2 amplification, HER2 amplification and MET amplification were 29.5 %, 12.9 %, 1.51 %, 2.27 %, 3.03 % and 0.75 %, respectively, in the Spanish population and 7.14 %, 5.71 %, 7.86 %, 5.71 %,4.29 % and 2.14 %, respectively, in the Chinese population. For the gene NTRK1, 11 samples showed signal apart companied amplified using FISH break-apart probes but none of them demonstrated genetic fusion by next-generation sequencing. As to clinicopathological characteristics, patients carrying IDH1/2 mutation showed longer overall survival in the Chinese population, while those carrying FGFR2 translocation tended to be younger in the Spanish population. For HER2, MDM2 and MET, gene amplification predicted protein high-expression, whereas FGFR2 translocation and NTRK1 amplification did not predict protein high-expression. Although many target drugs have been speeded up for approval such as BGJ398 for FGFR2 fusion positive ICC patients in western countries, the beneficiary populations are very small in China. The regular target drug such as trastuzumab for HER2 amplification and Crizotinib for MET amplification may be potential candidates in target treatment based on the Chinese population." @default.
• W3041486231 created "2020-07-16" @default.
• W3041486231 creator A5000315401 @default.
• W3041486231 creator A5009471600 @default.
• W3041486231 creator A5037171264 @default.
• W3041486231 creator A5048081699 @default.
• W3041486231 creator A5060578131 @default.
• W3041486231 creator A5064430125 @default.
• W3041486231 creator A5076695031 @default.
• W3041486231 creator A5081844561 @default.
• W3041486231 date "2020-09-01" @default.
• W3041486231 modified "2023-10-15" @default.
• W3041486231 title "Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population" @default.
• W3041486231 cites W1980595140 @default.
• W3041486231 cites W2015613033 @default.
• W3041486231 cites W2028700227 @default.
• W3041486231 cites W2072564984 @default.
• W3041486231 cites W2123767664 @default.
• W3041486231 cites W2368819226 @default.
• W3041486231 cites W2568488308 @default.
• W3041486231 cites W2603204749 @default.
• W3041486231 cites W2769909737 @default.
• W3041486231 cites W2792123367 @default.
• W3041486231 cites W2806800293 @default.
• W3041486231 cites W2890413816 @default.
• W3041486231 cites W2911070445 @default.
• W3041486231 cites W2953495640 @default.
• W3041486231 cites W3000958506 @default.
• W3041486231 cites W3003160806 @default.
• W3041486231 cites W4211234270 @default.
• W3041486231 cites W4245230906 @default.
• W3041486231 doi "https://doi.org/10.1016/j.prp.2020.153116" @default.
• W3041486231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32825971" @default.
• W3041486231 hasPublicationYear "2020" @default.
• W3041486231 type Work @default.
• W3041486231 sameAs 3041486231 @default.
• W3041486231 citedByCount "4" @default.
• W3041486231 countsByYear W30414862312021 @default.
• W3041486231 countsByYear W30414862312022 @default.
• W3041486231 countsByYear W30414862312023 @default.
• W3041486231 crossrefType "journal-article" @default.
• W3041486231 hasAuthorship W3041486231A5000315401 @default.
• W3041486231 hasAuthorship W3041486231A5009471600 @default.
• W3041486231 hasAuthorship W3041486231A5037171264 @default.
• W3041486231 hasAuthorship W3041486231A5048081699 @default.
• W3041486231 hasAuthorship W3041486231A5060578131 @default.
• W3041486231 hasAuthorship W3041486231A5064430125 @default.
• W3041486231 hasAuthorship W3041486231A5076695031 @default.
• W3041486231 hasAuthorship W3041486231A5081844561 @default.
• W3041486231 hasConcept C104317684 @default.
• W3041486231 hasConcept C111829193 @default.
• W3041486231 hasConcept C127848430 @default.
• W3041486231 hasConcept C138626823 @default.
• W3041486231 hasConcept C2777542201 @default.
• W3041486231 hasConcept C2908647359 @default.
• W3041486231 hasConcept C30481170 @default.
• W3041486231 hasConcept C501734568 @default.
• W3041486231 hasConcept C502942594 @default.
• W3041486231 hasConcept C54355233 @default.
• W3041486231 hasConcept C71924100 @default.
• W3041486231 hasConcept C7602840 @default.
• W3041486231 hasConcept C76818968 @default.
• W3041486231 hasConcept C86803240 @default.
• W3041486231 hasConcept C99454951 @default.
• W3041486231 hasConceptScore W3041486231C104317684 @default.
• W3041486231 hasConceptScore W3041486231C111829193 @default.
• W3041486231 hasConceptScore W3041486231C127848430 @default.
• W3041486231 hasConceptScore W3041486231C138626823 @default.
• W3041486231 hasConceptScore W3041486231C2777542201 @default.
• W3041486231 hasConceptScore W3041486231C2908647359 @default.
• W3041486231 hasConceptScore W3041486231C30481170 @default.
• W3041486231 hasConceptScore W3041486231C501734568 @default.
• W3041486231 hasConceptScore W3041486231C502942594 @default.
• W3041486231 hasConceptScore W3041486231C54355233 @default.
• W3041486231 hasConceptScore W3041486231C71924100 @default.
• W3041486231 hasConceptScore W3041486231C7602840 @default.
• W3041486231 hasConceptScore W3041486231C76818968 @default.
• W3041486231 hasConceptScore W3041486231C86803240 @default.
• W3041486231 hasConceptScore W3041486231C99454951 @default.
• W3041486231 hasFunder F4320321001 @default.
• W3041486231 hasFunder F4320335787 @default.
• W3041486231 hasIssue "9" @default.
• W3041486231 hasLocation W30414862311 @default.
• W3041486231 hasOpenAccess W3041486231 @default.
• W3041486231 hasPrimaryLocation W30414862311 @default.
• W3041486231 hasRelatedWork W1607835248 @default.
• W3041486231 hasRelatedWork W2071249067 @default.
• W3041486231 hasRelatedWork W2106534477 @default.
• W3041486231 hasRelatedWork W2347970638 @default.
• W3041486231 hasRelatedWork W2353678915 @default.
• W3041486231 hasRelatedWork W2384694942 @default.
• W3041486231 hasRelatedWork W2385076984 @default.
• W3041486231 hasRelatedWork W2591528425 @default.
• W3041486231 hasRelatedWork W3015296716 @default.
• W3041486231 hasRelatedWork W4225254934 @default.
• W3041486231 hasVolume "216" @default.
• W3041486231 isParatext "false" @default.
• W3041486231 isRetracted "false" @default.

• next